FDA Grants Priority Review of Epcoritamab (EPKINLY): A Significant Step in Lymphoma Treatment [VIDEO EXCLUSIVE] Lymphoma 3 Mins Read27 The FDA granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp. This subcutaneously administered T-cell engaging bispecific…
